How Effective Is Bimzelx for Moderate-to-Severe Plaque Psoriasis?
Bimzelx (bimekizumab-bkzx), approved by the FDA in 2023, treats adults with moderate-to-severe plaque psoriasis. In phase 3 BE RADIANT and BE READY trials, 85-91% of patients achieved PASI 90 (90% skin clearance) at week 16, compared to 7% on placebo. About 60% reached PASI 100 (complete clearance). These results held through week 52 in extension studies, outperforming some IL-17 inhibitors like ixekizumab.[1][2]
Does Bimzelx Work for Psoriatic Arthritis?
For active psoriatic arthritis (PsA), BE OPTIMAL and BE COMPLETE trials showed 45-50% of patients hit ACR50 (50% joint improvement) at week 16, versus 7-10% on placebo. Skin clearance was strong, with 60% achieving PASI 90. It works even in patients previously on TNF inhibitors.[1][3]
What About Hidradenitis Suppurativa Results?
FDA-approved in 2024 for moderate-to-severe hidradenitis suppurativa (HS). BE HEARD I and II trials reported 45-50% of patients with HiSCR50 (50% lesion reduction, no abscess increase) at week 16, doubling placebo rates (around 25%). Long-term data to week 48 showed sustained response in responders.[1][4]
How Does Bimzelx Compare to Other Biologics?
Bimzelx targets both IL-17A and IL-17F, potentially explaining faster skin clearance than single-IL-17 blockers. Head-to-head vs. adalimumab (Humira) in psoriasis: 86% PASI 90 for Bimzelx vs. 48%. Against ustekinumab (Stelara), it showed superior PASI 90 (85% vs. 47%). Real-world data is emerging but aligns with trials.[1][2]
When Do Patients See Results and How Long Do They Last?
Improvements start by week 4; peak clearance by week 16. Maintenance dosing every 8 weeks sustains efficacy to 3+ years in trials. About 80-90% maintain high responses long-term if they respond early.[1]
What Real-World Evidence and Limitations Exist?
Post-approval studies confirm trial efficacy, with high satisfaction in registries. Non-responders (10-15%) often have severe baseline disease. No head-to-head PsA trials vs. newer drugs like deucravacitinib. Long-term safety data is solid, but rare serious infections occur.[1][5]
Patent Protection and Market Status
Bimzelx, from UCB, has U.S. patents expiring no earlier than 2038. No generic or biosimilar challenges yet. Check DrugPatentWatch.com for updates on exclusivity.[6]
[1]: FDA Bimzelx Label, https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761195s000lbl.pdf
[2]: Gordon et al., Lancet 2021 (BE RADIANT), https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00126-4/fulltext
[3]: Ritchlin et al., Lancet 2023 (BE OPTIMAL), https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(22)02326-7/fulltext
[4]: Zouboulis et al., NEJM 2023 (BE HEARD), https://www.nejm.org/doi/full/10.1056/NEJMoa2308871
[5]: Lebwohl et al., J Am Acad Dermatol 2024 (real-world review)
[6]: DrugPatentWatch.com, https://www.drugpatentwatch.com/p/tradename/BIMZELX